First-in-class Oral Therapeutic for IBD with Novel Mode of Action
MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that data from the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease will be presented in an oral session at the upcoming 2009 Digestive Disease Week (DDW) meeting. Traficet-EN is an orally-available small molecule drug that controls the inappropriate immune system response underlying inflammatory bowel diseases by blocking the CCR9 chemokine receptor. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system. DDW 2009 will be held on May 30 - June 4, 2009, at McCormick Place in Chicago, Illinois.
Satish Keshav, M.D., Ph.D., Department of Gastroenterology, John Radcliffe Hospital,
Abstract (#392): PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
Session/Track: IBD Controlled Clinical Trials - Immunology, Microbiology & Inflammatory Bowel Disease
Location: McCormick Place, Room E450B
Date/Time: Monday, June 1, 2009, 3:30-3:45 PM
About CCX282-B (Traficet-EN)
Traficet-EN is an orally-available small molecule drug which is administered in capsule form and which is believed to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking th
|SOURCE ChemoCentryx, Inc.|
Copyright©2009 PR Newswire.
All rights reserved